MX2020009396A - Metodos de uso y composiciones farmaceuticas de un inhibidor selectivo de syk. - Google Patents

Metodos de uso y composiciones farmaceuticas de un inhibidor selectivo de syk.

Info

Publication number
MX2020009396A
MX2020009396A MX2020009396A MX2020009396A MX2020009396A MX 2020009396 A MX2020009396 A MX 2020009396A MX 2020009396 A MX2020009396 A MX 2020009396A MX 2020009396 A MX2020009396 A MX 2020009396A MX 2020009396 A MX2020009396 A MX 2020009396A
Authority
MX
Mexico
Prior art keywords
methods
syk
pharmaceutical compositions
selective inhibitor
compound
Prior art date
Application number
MX2020009396A
Other languages
English (en)
Inventor
Anjali Pandey
Matthew Chapin
Harold Patterson
Yung Yueh Hsu
Mark Abelson
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2020009396A publication Critical patent/MX2020009396A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aquí se proporcionan métodos para usar inhibidores de Syk, tal como un inhibidor selectivo de Syk, el Compuesto 1 o una sal farmacéuticamente aceptable del mismo, en el tratamiento de enfermedades o condiciones del ojo alérgicas y/o inflamatorias. También se proporcionan composiciones farmacéuticas, en particular composiciones oftálmicas de gotas para los ojos, que comprenden el Compuesto 1 o una sal farmacéuticamente aceptable del mismo, útiles en los métodos.
MX2020009396A 2018-03-09 2019-03-08 Metodos de uso y composiciones farmaceuticas de un inhibidor selectivo de syk. MX2020009396A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641094P 2018-03-09 2018-03-09
US201862663999P 2018-04-27 2018-04-27
PCT/US2019/021402 WO2019173744A1 (en) 2018-03-09 2019-03-08 Methods of use and pharmaceutical compositions of a selective syk inhibitor

Publications (1)

Publication Number Publication Date
MX2020009396A true MX2020009396A (es) 2021-01-15

Family

ID=65818744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009396A MX2020009396A (es) 2018-03-09 2019-03-08 Metodos de uso y composiciones farmaceuticas de un inhibidor selectivo de syk.

Country Status (15)

Country Link
US (1) US20210052582A1 (es)
EP (1) EP3761986A1 (es)
JP (1) JP7417531B2 (es)
KR (1) KR20210018193A (es)
CN (2) CN112243375A (es)
AU (1) AU2019230220B2 (es)
BR (1) BR112020018377A2 (es)
CA (1) CA3093371A1 (es)
IL (1) IL277093A (es)
MX (1) MX2020009396A (es)
PH (1) PH12020551418A1 (es)
SG (1) SG11202008765UA (es)
TW (1) TWI805705B (es)
WO (1) WO2019173744A1 (es)
ZA (1) ZA202005459B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
KR101454674B1 (ko) 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
MX2010011463A (es) * 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
SG2014015085A (en) * 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
EP2897950A1 (en) * 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors

Also Published As

Publication number Publication date
SG11202008765UA (en) 2020-10-29
US20210052582A1 (en) 2021-02-25
TWI805705B (zh) 2023-06-21
AU2019230220A1 (en) 2020-10-08
KR20210018193A (ko) 2021-02-17
PH12020551418A1 (en) 2021-09-01
IL277093A (en) 2020-10-29
BR112020018377A2 (pt) 2021-03-09
AU2019230220B2 (en) 2025-01-30
CN119235862A (zh) 2025-01-03
JP2021517139A (ja) 2021-07-15
CA3093371A1 (en) 2019-09-12
EP3761986A1 (en) 2021-01-13
JP7417531B2 (ja) 2024-01-18
WO2019173744A1 (en) 2019-09-12
CN112243375A (zh) 2021-01-19
ZA202005459B (en) 2023-02-22
TW202002980A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
MX2021009673A (es) Moduladores de ror-gamma.
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
UY37098A (es) Moduladores de ror-gamma
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
CO2018011064A2 (es) Inhibidores de bromodominios
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
MX390814B (es) Compuestos y metodos para el tratamiento de enfermedades parasitarias.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2018003930A (es) Inhibidores de calicreína plasmática humana.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2021009371A (es) Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
CL2021003592A1 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos.
AR110481A1 (es) MODULADORES DE ROR g (RORg)